Department Neurology, St Thomas Rutherford Hospital, Murfreesboro, 1700 Medical Center Pkwy, Murfreesboro, TN, 37129, USA.
Department of Neurology, Stanford University, Stanford, CA, USA.
BMC Neurol. 2022 Nov 4;22(1):408. doi: 10.1186/s12883-022-02943-4.
Mixed data exist regarding the association between hyperglycemia and functional outcome after acute ischemic stroke when accounting for the impact of leptomeningeal collateral flow. We sought to determine whether collateral status modifies the association between treatment group and functional outcome in a subset of patients with large vessel occlusion enrolled in the Stroke Hyperglycemia Insulin Network Effort (SHINE) trial.
In this post-hoc analysis, we analyzed patients enrolled into the SHINE trial with anterior circulation large vessel occlusion who underwent imaging with CT angiography prior to glucose control treatment group assignment. The primary analysis assessed the degree to which collateral status modified the effect between treatment group and functional outcome as defined by the 90-day modified Rankin Scale score. Logistic regression was used to model the data, with adjustments made for thrombectomy status, age, post-perfusion thrombolysis in cerebral infarction (TICI) score, tissue plasminogen activator (tPA) use, and baseline National Institutes of Health Stroke Scale (NIHSS) score. Five SHINE trial centers contributed data for this analysis. Statistical significance was defined as a p-value < 0.05.
Among the 1151 patients in the SHINE trial, 57 with angiographic data were included in this sub-analysis, of whom 19 had poor collaterals and 38 had good collaterals. While collateral status had no effect (p = 0.855) on the association between glucose control treatment group and functional outcome, patients with good collaterals were more likely to have a favorable functional outcome (p = 0.001, OR 5.02; 95% CI 1.37-16.0).
In a post-hoc analysis using a subset of patients with angiographic data enrolled in the SHINE trial, collateral status did not modify the association between glucose control treatment group and functional outcome. However, consistent with prior studies, there was a significant association between good collateral status and favorable outcome in patients with large vessel occlusion stroke.
ClinicalTrials.gov Identifier is NCT01369069. Registration date is June 8, 2011.
当考虑到软脑膜侧支循环的影响时,关于高血糖与急性缺血性卒中后功能结局之间的关联存在混合数据。我们试图确定在 Stroke Hyperglycemia Insulin Network Effort (SHINE) 试验中纳入的大血管闭塞患者亚组中,侧支状态是否会改变治疗组与功能结局之间的关联。
在这项事后分析中,我们分析了在接受葡萄糖控制治疗组分配前接受 CT 血管造影成像的前循环大血管闭塞患者的 SHINE 试验。主要分析评估了侧支状态在多大程度上改变了治疗组与功能结局之间的关系,功能结局定义为 90 天改良 Rankin 量表评分。使用逻辑回归对数据进行建模,调整了取栓状态、年龄、灌注后脑梗死溶栓治疗 (TICI) 评分、组织型纤溶酶原激活物 (tPA) 的使用以及基线国立卫生研究院卒中量表 (NIHSS) 评分。SHINE 试验的 5 个中心提供了该分析的数据。统计学意义定义为 p 值 < 0.05。
在 SHINE 试验的 1151 名患者中,有 57 名患者有血管造影数据纳入本亚分析,其中 19 名患者侧支循环不良,38 名患者侧支循环良好。虽然侧支状态对葡萄糖控制治疗组与功能结局之间的关联没有影响(p=0.855),但侧支循环良好的患者更有可能获得良好的功能结局(p=0.001,OR 5.02;95%CI 1.37-16.0)。
在使用 SHINE 试验中纳入的具有血管造影数据的患者亚组进行的事后分析中,侧支状态并未改变葡萄糖控制治疗组与功能结局之间的关联。然而,与先前的研究一致,在大血管闭塞性卒中患者中,侧支状态良好与良好结局之间存在显著关联。
ClinicalTrials.gov 标识符为 NCT01369069。注册日期为 2011 年 6 月 8 日。